Alerta

AGENTS AND METHODS DIRECTED TO DISEASE-ASSOCIATED CELLS

Resumen de: WO2026047225A1

Provided herein are agents and methods suitable for the treatment of inflammatory diseases of the intestine. For instance, agents and methods are provided for the treatment of inflammatory bowel disease, Crohn's disease, ulcerative colitis, Celiac disease, and colitis-associated colorectal cancer.

COMPOSITIONS AND METHODS FOR IMMUNOLOGICAL TESTING OF STOOL

Resumen de: US20260060660A1

The present disclosure provides improved methods of processing a fecal sample by a human subject in which the fecal sample is collected at home and subsequently delivered to a medical diagnostics laboratory. As described herein, the means of collecting and processing the fecal sample can desirably reduce the number of steps undertaken by the human subject, including avoiding steps of removing or separating the fecal sample into multiple portions. Furthermore, the human subject does not have to perform an immunological test (e.g., a fecal immunochemical test (FIT) or an immunochemical fecal occult blood test (iFOBT)) at home.

Methods and compositions for prediction of response to a therapy of an inflammatory bowel disease

Resumen de: AU2026201149A1

Biomarkers that are indicative of the response to the therapy of the inflammatory bowel disease, including ulcerative colitis (UC) and Crohn’s disease (CD), are described. Also described are probes capable of detecting the biomarkers and related methods and 5 kits for predicting the response to the therapy of the inflammatory bowel disease. eb e b

Nano-enzyme coating recombinant probiotics as well as preparation method and application thereof

Resumen de: CN121592569A

The invention discloses nano-enzyme coating recombinant probiotics as well as a preparation method and application thereof, and belongs to the technical field of biotechnology and nano medicine. According to the invention, engineered Escherichia coli Nissle 1917 (ECN (DE3)) is taken as a host, and glutathione peroxidase (GPX) and glutathione reductase (GR) genes are over-expressed through a genetic engineering means, so that an efficient antioxidant enzyme system is constructed. And sequentially modifying chitosan and cerium dioxide nano-enzyme (CNP) on the surfaces of the thalli by using an electrostatic layer-by-layer self-assembly technology to form a protective coating. The nano-enzyme coating significantly improves the survival rate of the recombinant probiotics in severe environments such as simulated gastric acid (pH 2.5) and bile salt (0.3%), and enhances the ability of the recombinant probiotics to remove reactive oxygen species (ROS), including hydrogen peroxide, superoxide anions, hydroxyl free radicals and DPPH free radicals.

Ultrahigh-affinity nucleic acid aptamer for specifically recognizing CD4 protein by using Re-SILEX technology

Resumen de: CN121592655A

The invention discloses a method for screening an ultrahigh-affinity nucleic acid aptamer for specifically recognizing CD4 protein by using a Re-SILEX technology, and belongs to the technical field of nucleic acid. The invention aims to solve the technical problem of how to effectively detect or target CD4 protein. In order to solve the technical problem, the invention provides a nucleic acid aptamer, the nucleic acid aptamer is at least one of nucleic acid aptamers with the name of CD4rzj-4a, CD4rzj-2a, CD4rzj-5a, CD4rzj-6a, CD4rzj-1b, CD4rzj-3a and CD4rzj-1a, and the nucleic acid aptamer CD4rzj-4a is a nucleic acid molecule with the nucleotide sequence of SEQ ID NO: 6. The aptamer provided by the invention has excellent specific binding force, and has important application potential in the field of CD4 detection or targeting.

USE OF RIFAXIMIN IN SUBJECTS HAVING DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME

Resumen de: US20260099855A1

0000 Systems and methods are provided for authenticating, verifying, and tracking physical and digital assets through an integrated framework combining artificial intelligence, multi-sensor fusion, blockchain provenance, and quantum-secure processing. The system establishes a continuous provenance loop where real-time live capture, multi-sensor scanning, and expanded identifiers are analyzed by an AI decision engine to generate a unique multi-modal fingerprint. 0000 This fingerprint is encoded into one or more machine-readable identifiers immutably recorded on a blockchain ledger. A Genesis Certificate of Authenticity (COA) anchors the item's origin, ownership, and transfer history. Subsequent resales or transfers trigger smart contracts that automate royalty distribution and provenance updates. The value captured through these processes can be monetary, such as currency or royalties, or intrinsic, such as positive social impact derived from verified actions or good deeds. Quantum acceleration enhances pattern matching, anomaly detection, and cryptographic resilience across industries.

METHODS OF DISEASE ACTIVITY PROFILING FOR PERSONALIZED THERAPY MANAGEMENT

Resumen de: US20260099855A1

0000 Systems and methods are provided for authenticating, verifying, and tracking physical and digital assets through an integrated framework combining artificial intelligence, multi-sensor fusion, blockchain provenance, and quantum-secure processing. The system establishes a continuous provenance loop where real-time live capture, multi-sensor scanning, and expanded identifiers are analyzed by an AI decision engine to generate a unique multi-modal fingerprint. 0000 This fingerprint is encoded into one or more machine-readable identifiers immutably recorded on a blockchain ledger. A Genesis Certificate of Authenticity (COA) anchors the item's origin, ownership, and transfer history. Subsequent resales or transfers trigger smart contracts that automate royalty distribution and provenance updates. The value captured through these processes can be monetary, such as currency or royalties, or intrinsic, such as positive social impact derived from verified actions or good deeds. Quantum acceleration enhances pattern matching, anomaly detection, and cryptographic resilience across industries.

A METHOD OF IMMUNE MODULATION BY MODULATING ABCF1

Resumen de: US20260099855A1

0000 Systems and methods are provided for authenticating, verifying, and tracking physical and digital assets through an integrated framework combining artificial intelligence, multi-sensor fusion, blockchain provenance, and quantum-secure processing. The system establishes a continuous provenance loop where real-time live capture, multi-sensor scanning, and expanded identifiers are analyzed by an AI decision engine to generate a unique multi-modal fingerprint. 0000 This fingerprint is encoded into one or more machine-readable identifiers immutably recorded on a blockchain ledger. A Genesis Certificate of Authenticity (COA) anchors the item's origin, ownership, and transfer history. Subsequent resales or transfers trigger smart contracts that automate royalty distribution and provenance updates. The value captured through these processes can be monetary, such as currency or royalties, or intrinsic, such as positive social impact derived from verified actions or good deeds. Quantum acceleration enhances pattern matching, anomaly detection, and cryptographic resilience across industries.

Application of E3 ubiquitin ligase RNF219 in preventing or treating inflammatory diseases

Resumen de: CN121570596A

The invention relates to the technical field of biological medicines, in particular to application of E3 ubiquitin ligase RNF219 in preventing or treating inflammatory diseases. The invention provides an application of a substance for inhibiting the activity of RNF219 protein or a substance for reducing the content of RNF219 protein in preparation of drugs for preventing or treating inflammatory diseases, especially drugs for preventing or treating sepsis and colitis. According to the application, a mouse acute infection model is constructed to prove that RNF219 defect inhibits the inflammatory reaction degree and inflammatory injury induced by LPS (Lipopolysaccharide); in a mouse with DSS-induced colitis, the RNF219 defect can delay the disease progress of the mouse colitis and improve the inflammatory phenotype of the mouse. Therefore, the function of the RNF219 in natural immune response is defined, and the RNF219 has important scientific significance on prevention and treatment of immune inflammation related diseases such as sepsis and inflammatory bowel diseases.

基于肠脑轴调控的治疗剂的生物芯片筛选方法及其应用

Resumen de: CN121575078A

本发明涉及生物医学工程，公开了一种基于肠脑轴调控的治疗剂的生物芯片筛选方法及其应用。该筛选方法包括以下步骤：采用表面经仿生化处理的超表面等离子共振生物芯片，进行肠壁细胞培养或者小胶质细胞培养获得肠壁细胞贴壁或者小胶质细胞贴壁的芯片板，在细胞贴壁的芯片板内加入含化疗药物或脂多糖的培养基进行培养I，再除去培养基、加入待测治疗剂进行培养II得到培养液，检测所述培养液中肠壁细胞或者小胶质细胞的细胞修复效果；筛选获得对肠壁细胞和/或小胶质细胞具有修复作用的治疗剂。该筛选方法能够从多个待测治疗剂中高效、准确地筛选出兼具肠道调节与神经保护双重功效的治疗剂，且能够实现无标记、实时在线动态监测与探究治疗剂和细胞的相互作用情况。

ANTI-TREM-1 ANTIBODIES AND USES THEREOF

Resumen de: US20260055183A1

Provided herein are methods of identifying subjects suitable for an anti-TREM-1 antibody (i.e., antagonistic anti-TREM-1 antibody) treatment comprising measuring an expression level of a TREM-1 associated gene. Also disclosed herein are methods of determining efficacy of an anti-TREM-1 antibody comprising measuring an expression level of a TREM-1 associated gene. Methods of identifying non-responder to a standard of care treatment and methods of treating a disease or disorder (e.g., inflammatory bowel disease) with an anti-TREM-1 antibody are also disclosed.

SYSTEMS AND METHODS FOR PREDICTING RESPONSE TO ANTI-TNF THERAPIES

Resumen de: US20260057960A1

Disclosed herein are methods and systems for administering therapy to subjects who have been determined to display or not display a gene expression response signature established to distinguish between responsive and non-responsive prior subjects who have received the therapy. The subject and prior subjects may suffer from a disease, disorder, or condition for which it is desired to predict whether the subject will respond to the therapy. In an aspect, the disease, disorder, or condition may be an autoimmune disorder such as ulcerative colitis. The subject may be administered an anti-TNF therapy or an alternative to anti-TNF therapy based upon predictions provided by methods and systems described herein.

METHOD, PROGRAM, AND APPARATUS FOR DETECTING SMALL INTESTINAL BACTERIAL OVERGROWTH

Resumen de: US20260053426A1

Embodiments include a method for detecting small intestinal bacterial overgrowth, SIBO, the method comprising: obtaining data representing a time series of readings from gas sensor hardware housed within an ingestible capsule device orally ingested by a subject, identifying the data corresponding to timing of passage through the small intestine, and determining whether or not the data indicates presence of SIBO.

Crohn disease auxiliary prediction method and device based on machine learning

Resumen de: CN121565478A

The invention relates to a Crohn disease auxiliary prediction method based on machine learning. The method comprises the following steps: obtaining related prediction data of a user; whether missing items exist in the user related prediction data is judged, if yes, an alarm is given to remind a user to supplement, if the user confirms that supplement cannot be carried out, self-adaptive complementation is carried out, and finally to-be-predicted data is formed; inputting the to-be-predicted data into a pre-established Crohn disease auxiliary prediction model, and outputting a prediction result by the Crohn disease auxiliary prediction model; the Crohn disease auxiliary prediction model is constructed based on an XGBoost model; and visually displaying the prediction result to inform a user. According to the method, when the data input by the user is missing, the user can be reminded to supplement, if the data cannot be supplemented, self-adaptive complementation is carried out, the prediction accuracy of the model is improved, Crohn disease risk prediction can be carried out according to the existing indexes of the patient, the user can conveniently find related risks in time, and the user experience is improved. And the diagnosis and treatment efficiency of the user is improved.

基于荧光探针的ATP水解酶抗体高效筛选法

Resumen de: CN121559077A

本发明公开了基于荧光探针的ATP水解酶抗体高效筛选法，包括生化体系和细胞体系两种检测方案，在生化体系中，通过定量ENTPD2蛋白水解ATP后剩余量，直接计算抗体抑制率；在细胞体系中，利用过表达ENTPD2的细胞验证抗体对跨膜酶的抑制功能。该生化体系方法无需抗体纯化，仅需5-15μL B细胞上清液即可完成初筛，筛选准确度高(细胞体系可用作验证筛选得到的抗体)，与体内药效结果一致，适用于抗ENTPD2抗体药物的开发，显著降低研发成本。

潰瘍性大腸炎に関与する遺伝子の抗ＩＬ－２３Ｐ１９抗体調節

Resumen de: US2024254217A1

The present disclosure generally relates to methods of treating and diagnosing ulcerative colitis. The methods are particularly suitable for treating and diagnosing a specific sub-group of patients with ulcerative colitis. The methods are also particularly suitable for treating and diagnosing urgency in a patient having or suspected of having ulcerative colitis. The methods are also particularly suitable for treating and diagnosing stool frequency and bowel urgency in a patient having or suspected of having ulcerative colitis.

Application of Slc36a1 agonist in preparation of medicine for preventing and/or treating colitis

Resumen de: CN121512985A

The invention provides application of an Slc36a1 agonist in preparation of a medicine for preventing and/or treating colitis, and belongs to the technical field of biology. According to the invention, 4-GBA or sarcosine is applied to a colitis model mouse, and clinical and histological phenotypes of DSS-induced colitis can be significantly improved. According to experiments of colonic organs and mice, 4-GBA enhances intestinal mucosal barrier and promotes intestinal homeostasis by up-regulating Slc36a1. According to the invention, 4-GBA or sarcosine molecules targeting Slc36a1 are taken as a core, and the limitation of an existing treatment strategy is broken through by synchronously solving a linkage mechanism of stem cell regeneration-goblet cell differentiation-mucous barrier repair.

Anti-TL1A antibody therapy methods

Resumen de: CN121532526A

The present disclosure provides methods and compositions for determining the risk of a patient unresponsive to a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody, and methods and compositions for treating inflammatory bowel disease (IBD) with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.

BIOMARKERS OF INFLAMMATORY BOWEL DISEASES (Machine-translation by Google Translate, not legally binding)

Resumen de: ES3055703A1

Biomarkers of inflammatory bowel diseases. The present invention relates to a method for early determination of whether a subject has an inflammatory bowel disease, comprising determining the expression product level of at least one biomarker, from a biological sample of a subject, selected from: ATRN, PRDX4, MOAB and AZU1. (Machine-translation by Google Translate, not legally binding)

PROPHYLACTIC OR THERAPEUTIC AGENT FOR CROHN'S DISEASE AND METHOD FOR EXAMINING CROHN'S DISEASE

Resumen de: WO2026034527A1

Provided are a prophylactic or therapeutic agent for Crohn's disease, and a method for examining Crohn's disease. The prophylactic or therapeutic agent for Crohn's disease contains at least one selected from the group consisting of a RUNX2 inhibitor and a BHLHE40 inhibitor. The method for examining Crohn's disease includes (1) a step for detecting a protein and/or mRNA of at least one gene selected from the group consisting of RUNX2 and BHLHE40 in digestive tract-derived immune cells collected from a subject.

SMAD7 INHIBITORY ANTISENSE OLIGONUCLEOTIDES (ASO) FOR TREATING POUCHITIS AND METHODS OF USING THE SAME

Resumen de: WO2024200594A1

Provided herein are methods for treating or preventing pouchitis comprising administering a SMAD7 antisense oligonucleotide or pharmaceutical formulations comprising the SMAD7 antisense oligonucleotide.

METHODS OF CLASSIFYING AND TREATING INFLAMMATORY BOWEL DISEASE

Resumen de: WO2024206308A2

Embodiments of the disclosure encompass methods and compositions for treating and/or identifying subjects having Inflammatory Bowel Disease (IBD). In certain embodiments, methods include measuring taxa occurrence frequencies in at least one microbiome sample from a subject suspected or having or being at risk for having IBD when certain taxa are enriched in the microbiome and/or when certain taxa are deficient in the microbiome, and particularly upon classification of their microbiome based on a taxa enrichment profile. In certain embodiments, an individual is determined to be a suitable donor for fecal microbiota transplant or is determined not to be a suitable donor for FMT based on classification of the taxa profile of their microbiome.

Multi-index content determination method of fructus aurantii immaturus and rhizoma atractylodis bowel-relaxing granules

Resumen de: CN121499685A

The invention discloses a multi-index content determination method of hovenia acerba and rhizoma atractylodis bowel-relaxing granules, and belongs to the technical field of traditional Chinese medicine detection. The invention establishes a high performance liquid chromatography method for simultaneously determining nine components including caffeic acid, chicoric acid, naringin, naringin, hesperidin, neohesperidin, chrysophanol, aurantio-obtusin and atractylenolide I in a preparation, and the content of the components is calculated through a relative correction factor by taking caffeic acid as an internal reference by adopting a quantitative analysis of multi-components by single marker. According to the method, effective detection of the immature bitter orange medicinal material and the immature bitter orange base source is realized, and the immature bitter orange and the sweet orange base source of the traditional Chinese medicine immature bitter orange can be accurately distinguished, so that more comprehensive and accurate quality control of the traditional Chinese medicine is realized, and the stability and consistency of clinical efficacy of the traditional Chinese medicine are guaranteed.

METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST

Resumen de: EP4417707A2

This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.

Citrus hybrid offspring authenticity identification method based on whole genome SNP (Single Nucleotide Polymorphism) analysis

Nº publicación: CN121472476A 06/02/2026

Solicitante:

HUAZHONG AGRICULTURAL UNIV
HUBEI HONGSHAN LABORATORY
SICHUAN TAORAN CITRUS NEW VARIETIES RES CO LTD
\u534E\u4E2D\u519C\u4E1A\u5927\u5B66
\u6E56\u5317\u6D2A\u5C71\u5B9E\u9A8C\u5BA4
\u56DB\u5DDD\u9676\u7136\u67D1\u6854\u65B0\u54C1\u79CD\u7814\u7A76\u6709\u9650\u516C\u53F8

Resumen de: CN121472476A

The invention discloses a citrus hybrid offspring authenticity identification method based on whole genome SNP (Single Nucleotide Polymorphism) analysis. According to the invention, a genome typing technology in a whole genome range is adopted, and a set of discrimination system capable of accurately identifying real hybrid offspring is established through high-density SNP (Single Nucleotide Polymorphism) marker analysis and an IBD (Identity by means of an algorithm. The method breaks through the limitation of a traditional method on hybrid filial generation identification, and provides reliable technical support for breeding practice.